A translationally silent KRASG60G mutation, preventing the formation of a cryptic splice donor site and enabling expression of KRAS(Q61K), reveals a vulnerability in RASQ61 cancers that are therapeutically exploitable in a mutant-selective manner.
- Yoshihisa Kobayashi
- Chhayheng Chhoeu
- Pasi A. Jänne